Loading
A phase 1/2 trial of Alpelisib, Tucatinib and Fulvestrant in HER2-positive breast cancer, run by Criterium, Inc., active and no longer recruiting.
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. is a phase 1/2 interventional study registered as NCT05230810 by Criterium, Inc., with 40 participants enrolled, started 2022-08-25 and due to reach its primary completion in 2026-03-30. Interventions recorded: Alpelisib, Tucatinib and Fulvestrant.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Fulvestrant and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Fulvestrant and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Fulvestrant and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Criterium, HER2 tyrosine kinase inhibitors, Tucatinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Pfizer (incl. Seagen), Small-molecule kinase inhibitors and the tag pipeline.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Fulvestrant, Pfizer (incl. Seagen) and the tag pipeline.